3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK

Trial Profile

3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Anatabine (Primary)
  • Indications Alzheimer's disease; Inflammation; Multiple sclerosis; Neurological disorders
  • Focus Pharmacokinetics
  • Sponsors Rock Creek Pharmaceuticals Inc
  • Most Recent Events

    • 03 Feb 2016 Interim report of the pharmacodynamic results of this trial published in a Rock Creek Pharmaceuticals media release.s
    • 19 Oct 2015 Status changed from active, no longer recruiting to completed according to a Rock Creek Pharmaceuticals media release.
    • 10 Aug 2015 According to a Rock Creek Pharmaceuticals Inc. media release, part two of this study will be conducted with a protocol amendment that primarily evaluates the effects of food on PK parameters. The dosing for part two is expected to commence and be completed within the third quarter of 2015. amendment. Part three is expected to be complete along with prelimnary results in the third quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top